More on Teva Q2 results

• Teva Pharmaceutical Industries (NYSE:TEVA) Q2 results: Total Revenues: $5,045M (+2.5%), Generic Medicine: $2,515M (+4.3%), Specialty Medicine: $2,027M (-1.2%); Operating Income: $1,094M (+14.8%); Net Income: $745M (-26.8%); EPS: $0.87 (-27.5%); CF Ops: $1,053M (+20.3%).
• Product sales: Copaxone: $939M (-12.2%), Treanda: $190M (+7.3%), ProAir: $133M (+15.7%), Women's Health: $128M (+19.6%).
• 2014 Guidance: no update provided.